MetaVia Inc. Annual Report: A Simple Breakdown

I’ve put together this guide to help you understand MetaVia Inc.’s performance. Think of this as a plain-English breakdown—no confusing Wall Street jargon, just the facts you need to decide if this company fits your portfolio.

1. What does this company do?

MetaVia is a small biotech firm based in Cambridge with a team of eight. They focus on two major health challenges: obesity and MASH, a serious fatty liver condition. They operate like a research lab, outsourcing manufacturing and clinical trials to keep costs low. Their two main assets are vanoglipel (DA-1241) for MASH and DA-1726 for obesity.

2. The Big News: Clinical Trial Wins

This year was a major step forward for their drug pipeline:

• Vanoglipel (MASH): A Phase 2a study confirmed the drug works. In a 12-week trial, patients taking 100 mg twice daily saw a significant drop in liver fat and better blood sugar control compared to the placebo group.
• DA-1726 (Obesity): This is their "next-gen" weight loss candidate. Recent Phase 1 results were encouraging. Patients on the 48 mg dose lost 9.1% of their body weight (about 21 lbs) over 56 days. The drug is designed to burn fat while preserving muscle, which sets it apart from current market leaders.

3. The Financial Reality: A "Going Concern" Warning

This is the most important part for you to understand: MetaVia is in a high-risk financial position.

• No Revenue: They haven't sold a single product yet. They reported a $13 million loss for the year ending December 31, 2025. Since they started, they have lost $148.8 million, mostly on research.
• The "Going Concern" Flag: Their auditors issued a "going concern" warning. This means the company does not have enough cash to fund operations for the next 12 months without raising more money.
• The Runway: As of December 31, 2025, they held $18.2 million in cash. After a $15 million stock sale in January 2026, they have enough money to last until the fourth quarter of 2026. After that, they will need a large cash infusion to start their next round of trials.

4. What This Means for You

Because they have no income, they fund research by selling more shares. This is called equity financing.

• Dilution: Every time they issue new shares, your percentage of ownership in the company shrinks. In 2025, they issued 4.2 million new shares, and the January 2026 sale added another 2.5 million. This often pushes the stock price down because the company's value is now spread across more shares.
• The "Big Pharma" Race: They are competing against giants like Eli Lilly and Novo Nordisk, who have massive budgets. To survive, MetaVia must prove their drugs are safer or more effective in larger trials. Also, new government rules allow Medicare to negotiate drug prices, which could lower future profits.

5. What’s Next for Investors

The company is moving ahead with its clinical roadmap. In 2026, they will focus on finding the best dose for DA-1726. Investors should look for new data by late 2026.

Decision Checklist:

• Risk Tolerance: Are you comfortable with a company that has no revenue and relies on selling shares to stay afloat?
• Timeline: Are you prepared to wait until late 2026 for the next major data release?
• Market Position: Do you believe MetaVia’s specific approach to weight loss (preserving muscle) can compete with the established industry leaders?